Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CLIAC Reaffirms Quality, Comparability In Waiver Criteria Proposal To HHS

This article was originally published in The Gray Sheet

Executive Summary

Quality control testing requirements should be included in manufacturer instructions for CLIA-waived assays to compensate for the potential inexperience of lab personnel, the Clinical Laboratory Improvement Advisory Committee (CLIAC) is urging HHS
Advertisement

Related Content

CLIA Waiver Withdrawal Option Likely Will Be Explored By CDC Subcommittee
CLIA Waiver Withdrawal Option Likely Will Be Explored By CDC Subcommittee
FDA Pulls CLIA Waiver Guidance, CMS To Take Lead Drafting New Criteria
FDA Pulls CLIA Waiver Guidance, CMS To Take Lead Drafting New Criteria
HHS Sign-Off Critical To CLIA Waiver Proposal: FDA Criteria At Odds With CMS'
Advertisement
UsernamePublicRestriction

Register

MT016078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel